kraiglabs.com
120 North Washington Square, Suite 805
Lansing, Michigan 48933
Telephone: (517) 336-0807
Email: corporate@KraigLabs.com
Next Company Event:
Kraig Biocraft Laboratories To Hold Conference Call
[Details To Be Announced]
Click Here to Listen to KBLB Conference Call March 2012
Click Here to Listen to KBLB Conference Call June 2011
Click Here to Listen to KBLB Conference Call Oct 2010
Quarterly and Annual Reporting to the SEC is available on the Company's Website and EDGAR.
* Financial Statements * SEC Filings *
Outstanding Shares as of December 31, 2012
603,269,838
A/S 10 Billion
For issues or questions relating to share certificates or the transfer of securities please contact the company's transfer agent:
Registrar and Transfer Company
10 Commerce Drive
Cranford, NJ 07016-3572
(800) 866-1340
Photos: Magnified view of transgenic silk, silkworm ready to spin, spun silkworm cocoons and silk made with spider silk sequences.
Kraig Biocraft Laboratories, Inc. (KBLB) is the first company with a commercially feasible spidersilk to be mass produced.
Kraig Labs is a biotechnology company focused on the development of commercially significant high performance polymers and technical fibers. Kraig Lab's focus has been on the production of a transgenic silkworm incorporating specific gene sequences from the golden orb weaving spider. These specific gene sequences inserted are to enable the silkworm to spin a new recombinant fiber which incorporates spider silk proteins. With the scientific breakthrough announced on September 29, 2010, Kraig Labs is now working to commercialize the transgenic silkworms to compete in the garment industry silk market. The value for the chinese raw silk market alone is 3-5 billion per annum. With the creation of 20 seperate transgenic silkworms, all with unique properties, Kraig Labs is now working at an accelerated pace to build upon their first generation transgenic organisms to develop their second generation of transgenic silkworm incorporating spider silk proteins. The scientists nearly doubled the strength of the silkworm with these specific spider gene insertions. Their second generation of transgenics are expected to be complete in 2011. These second generation organisms are to be compared with the strength, flexibility and resiliency of the native spider in which the gene sequences are derived from. These fibers which will match the strength of spider silk are expected to compete in the technical textiles market valued in excess of 120 billion per annum. The 3rd generation organisms are currently in the planning phase. These organisms are expected to spin fibers exceeding the strength of native spiders and may incorporate gene sequences that release an antibiotic, or to help reduce scarring with use in bandages.
Kraig Biocraft Laboratories has a sponsored research and development program with the University of Notre Dame, and the University of Wyoming. The genetic work is occurring at the University of Notre Dame, headed by Dr Malcolm Fraser, Phd. The gene sequences are derived from Dr. Randy Lewis's(University of Wyoming) patented gene sequences of the golden orb weaving spider. Kraig labs is paying for all expenses incurred for this research and development program, and thus Kraig Labs has exclusive global commercialization rights with the technologies developed, including methods, organisms, and fibers produced.
September 29, 2010 Press Conference Held At Notre Dame
Must see Videos:
Kraig Biocraft Laboratories, Inc. Has Its Breakthrough
Scientific Achievement Published
Silkworms Transformed with Chimeric Silkworm/Spider Silk Genes Spin Composite Silk Fibers with Improved Mechanical Properties.
http://www.pnas.org/content/109/3/923.long
INDUSTRY / SCIENTIFIC JOURNAL ARTICLES :
Jan - Feb Issue: Quality Fabric Of The Month:
Spider Silk Potential Unleashed:
http://www.textileworld.com/Articles/2012/January/Jan-Feb_issue/Departments/QFOM_Spider_Silk.html
Techtextil North America 2012 Back To Pre-Recession Level A Great Indicatory That The Industry Is Growing And Moving Forward:
http://www.textileworld.com/Articles/2012/May/Techtextil_North_America_2012_Back_To_Pre-Recession_Level.html
Kraig Biocraft creates composite spider silk fibre:
http://www.fibre2fashion.com/news/textile-news/newsdetails.aspx?news_id=120153
Kraig Biocraft Laboratories Develops "Big Red" Recombinant Spider Silk: http://www.textileworld.com/Articles/2013/January/Kraig_Biocraft_Develops_Big_Red_Recombinant_Spider_Silk.html
"This new type of fiber was designed to be a combination of spider silk proteins,
silkworm silk proteins and protein from an unrelated species," Thompson said.
"From a genetic perspective, what significantly differentiates this material from
our Monster Silk™ is the unique spider silk genetic sequence that we used,
which we designed to increase strength to weight ratios. Another important
difference is the incorporation of a unique protein, which gives the new
fiber its designation as 'red.' - Kim Thompson, CEO, Kraig Biocraft-
- Strands of Big Red silk fibres in the cocoon -
Commercialising the science of spider silk:
http://ei.wtin.com/2013/01/24/commercialising_the_science_of_spider_silk/
MANAGEMENT
Kim Thompson, Founder and CEO
As the CEO of the company, Mr. Thompson is the only member of the scientific advisory board who is also
a part of the corporation's management. His formal education lies in the fields of economics and law.
He received his B.A. in Applied Economics from James Madison College at Michigan State University.
He received his Juris Doctorate from the University of Michigan Law School in 1994.
Mr. Thompson founded Kraig Biocraft Laboratories in his pursuit of the development of new biotechnologies
with industrial applications. As chairman of the scientific advisory board, he brings a unique perspective,and
acts as the primary liaison between the advisory board and the corporation.
Mr. Thompson brings a wealth of experience in business management and consultation to Kraig. Following
the completion of his undergraduate degree, Mr. Thompson joined California Craftsman, Inc. as a
Vice-President with primary responsibility for both marketing and human resources.
Kim Thompson was the director of business development at Franchise Venture Partners, LLC. He subsequently
joined the firm of Shearson, Lehman, Hutton where he specialized in equity trading and research of small cap
companies. Mr. Thompson received the highest series seven score for all Shearson brokers in his class nationwide.
His experience in those small cap equity markets has proven to be invaluable both in his legal and business successes.
Prior to becoming a public company CEO, Mr. Thompson was the founder and senior litigation partner in a California
commercial law firm where he worked as corporate and litigation counsel to privately held and public companies.
His many accomplishments in corporate law include winning and collecting in full what his firm believes to have been
the largest award of lost profits in a California commercial arbitration up to that time. An important part of his work was
winning victories on behalf of corporate clients in disputes over intellectual property and distribution rights. He has
represented business clients ranging from small start ups and micro caps to Fortune 100 companies.
With a background in business leadership and in advising public and private corporations, Kim Thompson continues
to bring a unique perspective to the successful management of business. His extensive business and legal background
enables him to create practical solutions to business problems and seize opportunities for growth.
Mr. Thompson is a member of the Triple Nine Society for persons with documented genius level IQs (having tested above
the 99.9th percentile). He is also active in the realm of science and invention where he has to his credit a number of
provisional patent applications including innovations in the areas of biotechnology, organic polymers, genetic engineering
and magnetic field manipulation, among others.
Conference Calls with Kim Thompson:
March 2012 KBLB Conference Call
March 2012 KBLB Conference Call (Transcript)
June 2011 KBLB Conference Call
October 2010 KBLB Conference Call
2 Audio Interviews with CEO Kim Thompson:
http://smallcapvoice.com/blog/4-16-08-audio-interview-with-kraig-biocraft-laboratories-inc-otcbb-kblb/
http://smallcapvoice.com/blog/5-21-08-audio-interview-with-kraig-biocraft-laboratories-inc-otcbb-kblb/
June 2011, Interview from Chartpoppers with Kraig Biocraft Laboratories CEO Kim Thompson (transcript):
Chartpoppers Interview with Kim Thompson (CEO, KBLB) June 8th 2011 (transcript)
January 2012, Interview from StockRadio.com with Kraig Biocraft Laboratories CEO Kim Thompson (transcript):
http://www.kraiglabs.com/Interview%20with%20Kim%20K%20Thompson%20Company%20CEO.htm
August 2012, Kim Thompsons Letter to Shareholders:
http://www.kraiglabs.com/shareholder-letter-080512.htm
PDF File:http://www.kraiglabs.com/pdf/Dear-Shareholder-08-05-2012-B.pdf
April 2013, Kim Thompsons Letter to Shareholders:
https://materials.proxyvote.com/Approved/50075W/20130318/OTHER_160541.PDF
BOARD OF SCIENTIFIC ADVISORS
Malcolm. J. Fraser, Jr. Ph.D.
Dr. Fraser received his Ph.D. from Ohio State University, and performed postdoctoral research at both Penn State University and Texas A & M University.
At Texas A & M he was a part of the team which developed the genetic expression system which is now a widely used methodology for producing organic
molecules, including pharmaceuticals, on an industrial scale.
He is the co-inventor of the gene splicing technology "piggyBac", as well as the inventor of various piggyBac improvement patents. It was his work on
piggy Bac which first caught the attention of Kraig Biocraft Laboratories.
He was recently selected as a fellow of the American Association for the Advancement of Science. This was awarded in recognition for his distinguished
contributionsto genetics and transgenesis, and for his discovery of the piggyBac transposable element and derived transgenic vector system.
In 2006, Dr. Fraser was awarded $2.5 million from the Bill and Melinda Gates Foundation to fund "deliverable technologies" in the field of transgenesis,
for the prevention of mosquito born disease.
Dr. Fraser is a member of the faculty at the University of Notre Dame, where he heads the Fraser Laboratory. The focus
of his work is molecular genetics.
He is the author or co-author of numerous scientific articles in the field of genetic engineering and gene manipulation.
Dr. Fraser's Audio interview with Quirks and Quarks Jan 14, 2012 :
http://www.cbc.ca/video/news/audioplayer.html?clipid=2186641369
Randy Lewis, Ph.D.
Dr. Lewis received his B.S. in chemistry from the California Institute of Technology. He received his M.S. in chemistry and his
Ph.D. in Biochemistry from the University of California, San Diego.
Dr. Lewis is internationally renowned for his work on spider silk. He is also the named inventor of a number of patents relating to spider silk polymers.
He was a member of faculty at the University of Wyoming, where he headed the Lewis Laboratory within the Department of Molecular Biology. He is
listed under emeritus faculty for the University of Wyoming.
Currently Dr. Randy Lewis is conducting his research at Utah State University. The study of spider silk polymers and their underlying genetics is still
a major focus of Dr. Lewis's research.
His recent publications include:
(1990) Xu, M. and Lewis, R.V. Structure of a Protein Superfiber: Spider Dragline Silk Proc. Natl. Acad. Sci. 87, 7120-24.
(1992) Hinman, M.B. and Lewis, R.V. Isolation of a Clone Encoding a Second Dragline Silk Fibroin, Nephila Clavipes Dragline
Silk is a Two Protein Fiber J.Biol. Chem 267: 19320-19324.
(1994) Stauffer, S., Cougill, S. and Lewis R.V. Mechanical Properties of Several Spider Silks. J. of Arachnology 22:5-11.
(1996) Lewis, R.V., Hinman, M., Kothakota, S. and Fournier, M. Expression and Purification of a Recombinant Spider Silk Protein:
A New Strategy for Producing Repetitive Proteins Protein Expression and Purification 7:400-406.
(1997) Parkhe, A.J., Seeley, S.K., Gardner, K., Thompson L. and Lewis, R.V. Structural Studies of Spider Silk Proteins in the Fiber,
J. of Molecular Recognition 10:1-6.
(1997) Liivak, O., Flores , A., Lewis, R.V. and Jelinski, L.W. Conformation of the Polyalanine Repeats in Minor Ampullate Gland Silk
of the Spider Nephila clavipes. Macromolecules 30:7127-31.
(1998) Colgin, M and Lewis, R.V. Spider Minor Ampullate Silk Proteins Contain New Repetitive Sequences and Highly Conserved
Non-silk-like "Spacer Regions" Protein Science 7:667-672.
(1998) Hayashi, C. and Lewis, R.V. Spider Flagelliform Silk Proteins J. of Mol. Biol. 275:773-784.
(1999) Hayashi, C.Y., Shipley , N.H. and Lewis, R.V., Hypotheses that Correlate the Sequence, Structure, and Mechanical Properties
of Spider Silk Proteins. ( International J. of Biological Macromolecules 24:271-275).
(2001) Gatesy, J., Hayashi, C.Y., Motriuk, D., Woods, J. and Lewis, R.V. Extreme Diversity, Conservation, and Convergence of Spider
Silk Fibroin Sequences Science 291:2603-05.
(2004) Gregory P. Holland, Randolph V. Lewis, and Jeffrey L.Yarger WISE NMR Characterization of Nanoscale Heterogeneity and
Mobility in Supercontracted Nephila clavipes Spider Dragline Silk, J. Am .Chem. Soc. 126: 5867-5872.
(2004) Hayashi CY, Blackledge TA, Lewis RV. Molecular and mechanical characterization of aciniform silk: uniformity of iterated
sequence modules in a novel member of the spider silk fibroin gene family. Mol Biol Evol . 21(10):1950-9.
(2004) M Tian, C Liu, and R Lewis, Analysis of Major Ampullate Silk cDNAs from Two Non-Orb-Weaving Spiders. Biomacromolecules
5(3): 657-661.
(2004) Brooks A.E. and Lewis, R.V., "Probing the Elastic Nature of Spider Silk in Pursuit of the Next Designer Fiber" in Biomedical
Sciences Instrumentation : Vol. 40, pg: 232 - 237.
(2004) Motriuk-Smith, M. and Lewis, R.V. "Brown Widow (Latrodectus Geometricus) Major Ampullate Silk Protein And Its Material
Properties" in Biomedical Sciences Instrumentation : Vol. 40, pg: 64-69.
((2005) Dagmara Motriuk-Smith, Alyson Smith, Cheryl Y. Hayashi, Randolph V. Lewis Analysis of the conserved N-terminal domains
in major ampullate spider silk proteins (in press, Biomacromolecules ).
Utah State University Presentation:
https://podcasts.usu.edu/MediaPlayer/player.html?filename=Podcasts/sunrise/Sunrise1202012
BBC Video with Randy Lewis Jan 16, 2012:
http://www.bbc.co.uk/news/science-environment-16554357
Artificial Spider SIlk: Wyoming Signatures Interview with Randy Lewis:
http://www.youtube.com/watch?v=2yAQ5e_c49w&feature=related
Donald L. Jarvis, Ph.D.
Dr. Jarvis received both his B.S. and M.S. in microbiology at Idaho State University . He received his Ph.D. in Virology at Baylor College of Medicine.
After earning his Ph.D. he trained in molecular cloning at Baylor. In 1987 he undertook postdoctoral studies on glycoprotein biosynthesis at Texas
A&M. In 1989, Dr. Jarvis moved into an independent position at Texas A&M.
In 1998, Dr. Jarvis accepted a position in the Department of Molecular Biology at the University of Wyoming . He received a professorship in 2000.
Dr. Jarvis heads a research laboratory within the University's Department of Molecular Biology which focuses on biochemistry, biosynthesis, and
practical genetic engineering applications. He has approximately eighteen patent applications and intellectual property licensing agreements to
his credit, including biosynthesis technologies and technologies with potential applications for pharmaceutical production.
He is the author and co-author of numerous scientific articles in the fields of biosynthesis, genetic engineering and biochemistry.
Dr. Jarvis's consulting appointments have included:
Novagen Corporation, Madison , WI 1996.
DuPont Agricultural Products, Wilmington , DE 1996-1997.
Invitrogen Corporation, Carlsbad , CA 1999-2002.
GlaxoSmithKline Biologicals, Belgium , 2005.
His recent publications include:
Jarvis, D.L., Hollister, J.R., and Aumiller, J.A. 2003. Development of novel transgenic insect cell lines that support humanized
glycoprotein production by baculovirus expression vectors. BioProcessing J. 2:30-34.
Hollister, J.R., Conradt, H.O., and Jarvis, D.L. 2003. Evidence for a sialic acid salvage pathway in lepidopteran insect cells.
Glycobiology 13:487-495.
Jarvis, D.L. 2003. Humanizing recombinant glycoprotein production in the baculovirus-insect cell expression system. Virology 310:1-7.
Tomiya, N., Howe, D., Aumiller, J.J., Pathak, M., Park, J., Palter, K., Jarvis, D.L., Betenbaugh, M.J., and Lee, Y.-C. 2003. Complex-type
biantennary N-glycans of recombinant human transferrin from Trichoplusia in insect cells expressing mammalian ß1,
4-galactosyltransferase and ß1,2-N-acetylglucosaminyltransferase II. Glycobiology 13:23-34.
Washburn, J.O., Chan, E.Y., Volkman, L.E., Aumiller, J.J., and Jarvis, D.L. 2003. Early biosynthesis of BV envelope fusion protein
gp64 enhances AcMNPV virulence in orally-infected Heliothis virescens . J. Virol. 77:280-290.
van Beek, N., Lu, A., Presnail, J., Davis, D., Greenamoyer, C., Joraski, K., Moore, L., Pierson, M., Herrmann, R., Flexner, L., Foster, J.,
Van, A., Wong, J., Jarvis, D., Hollingshaus, G., and McCutchen, B. 2003. Effect of signal sequence and promoter on the speed of action
of a genetically modified Autographa californica nucleopolyhedrovirus expressing the scorpion toxin LqhIT2. Biological Control, 27:53-64.
Vadaie, N. and Jarvis, D.L. 2004. Molecular cloning of a lepidopteran insect ß1,4N-acetylgalactosaminyltransferase with an unusually
broad substrate specificity, a functional role in N -glycoprotein biosynthesis, and a potential functional role in glycolipid biosynthesis.
J. Biol. Chem. 279:33501-33518.
Zhang, J.-H., Washburn, J.O., Jarvis, D.L. and Volkman, L.E. 2004. AcMNPV early gP64 synthesis mitigates developmental resistance
in orally infected noctuid hosts. J. Gen. Virol. 85:833-842.
Wang, Y., Oberly, L.W., Howe, D., Jarvis, D.L., and Murhammer, D.W. 2004. The effect of manganese superoxide dismutase expression
in baculovirus infected insect cells. Appl. Biochem. Biotech. 119:181-193.
Kost, T.A., Condreay, J.P., and Jarvis, D.L. 2005. Baculovirus: versatile vectors for protein expression in insect and mammalian cells.
Nature Biotechnology 23:567-575.
Aumiller, J.A., Hollister, J.R., and Jarvis, D.L. 2006. Molecular cloning and functional characterization of ß- N -acetylglucosaminidase genes
from Sf9 cells. Prot. Expr. Purif. 47:571-590.
Hill, D.R., Aumiller, J.J., Shi, X., and Jarvis, D.L. 2006. Isolation and characterization of a baculovirus vector that supports recombinant
glycoprotein sialylation by SfSWT-1 cells cultured in serum-free medium. Bioengr. Biotechnol., 95:37-47.
Shi, X. and Jarvis, D.L. 2006. A new method for the rapid amplification of cDNA ends of extremely GC-rich genes. Analyt. Biochem. 356:222-228.
Shi, X., Harrison, R.L., Hollister, J.R., Fraser, M.J., and Jarvis, D.L. 2007. Construction and characterization of new piggyBac vectors for
constitutive or inducible expression of heterologous gene pairs and the identification of a previously unrecognized activator sequence
in piggyBac . BMC Biotechnol. 7:5.
Shi, X. and Jarvis, D.L. 2007. Protein N-glycosylation in the baculovirus-insect cell system. In M.J. Fraser, G.W. Blissard, and J. Vlak (eds.).
Current Drug Targets, Bentham Press, London (in press).
BUSINESS ADVISORY BOARD
Henry Wendt (announced 11/09/2010)
Henry Wendt is the former CEO and Chairman of SmithKline Beecham, one of the world's largest and most successful corporations. He has an unparalleled
track record for fostering and managing corporate growth through mergers and acquisitions, as well as through organic growth and global marketing. In fact,
he is generally recognized as the principal architect of the successful merger that created SmithKline Beecham.
In his term as CEO of the pharmaceutical giant, Wendt focused on a "3 point strategy" to help strengthen the business.
His strategy consisted of increasing support of SmithKline's best products, such as Tagamet, weeding out less profitable products, and increasing shareholder
value. This strategy lead to the successful merger of SmithKline with UK-based Beecham Company. The creation of SmithKline Beecham (SKB), engineered by
Wendt and Beecham's chief, created the world's second largest pharmaceutical company in both prescription and over-the-counter drugs.
In addition to his groundbreaking leadership at SmithKline Beecham, Mr. Wendt literally wrote the book on successful strategies for corporate growth in the global
marketplace, Global Embrace: Corporate Challenges in a Transnational World, a 'must read' for corporate executives.
Mr. Wendt is the Co-Founder of Healthcare Investment Partners, as well as the Founder of Global Health Care Partners.
He is a graduate of Princeton University.
Raymond Kutsunai (announced 11/22/2010)
(no photo available)
Raymond Kutsunai's unique accomplishments and lifetime experiences have enabled him to forge a path that has left his mark on history and international
business.
Mr. Kutsunai grew up in pre-statehood Hawaii, the geographical and cultural hub that links North America and Asia . When he was a teenager he was sent to
Hiroshima to study Japanese and renew his family and cultural ties. Unfortunately, this was just prior to the outbreak of the Second World War. He attended
high school in Hiroshima. Unable to return to Hawaii during the war, he attended university in Japan.
Immediately after the war, Mr. Kutsunai was distinctively positioned to assist both the United States and the people of Japan. Upon his homecoming to the
United States , Mr. Kutsunai returned to school and completed his university degree at the University of Michigan .
Mr. Kutsunai subsequently rose rapidly through the ranks at SmithKline & French and was named General Manager of SmithKline & French Laboratories
Japan. He was able to parlay his business instincts and extensive understanding of the Japanese culture and business environment into stunning successes
for the Company's Japanese operations.
As remarkable as Mr. Kutsunai's incredible personal and professional experiences have been, they are exceeded by his loyalty to his family, friends, associates
and country.
Joe Cunning, Ph.D. (announced 01/14/2011)
Dr. Joe Cunning is a leading figure in the textile industry and member of the Textile Institute's governing board, with 45 years of experience in the fibers, textile
and apparel industry. He was awarded the Textile Institute's Medal for outstanding contribution to the industry in 2000. In 2010 he was presented with the
Textile Institute's Companion Membership award, as one of fifty living persons who have made a significant impact on the textile industry.
Dr. Cunning completed a highly successful 28 year career at DuPont, where he headed the pioneering research laboratory in Wilmington , and was in charge
of worldwide research on all fiber types. His manufacturing experience included worldwide responsibility for non-woven products, as well as polyester filament
and staple fibers.
In addition to his work on various corporate boards, Dr. Cunning served on the governing boards of the Fiber Society, vice-president of the Textile Institute, the
Technical Advisory Committee, and on the board of governors of the Iowa State University Foundation. In 1992, Cunning was named the National Textile
Center 's (a research consortium of eight universities) first Executive Director, a post he held for 12 years. Dr. Cunning is also the President of Cunning &
Associates, Ltd., a leading textile industry consulting firm.
Credit Randy Stewart Despite the huge potential of genetically modified animals outside of laboratory research, commercialisation of these animals has been extremely limited. Numerous factors, including negative consumer perception, regulatory hurdles, and limitations inherent to classical GM technologies, have kept the majority of GM animal applications within the realm of academic research. However genome editing using zinc finger nucleases could help develop new markets for the future commercialisation of GM animals.
Genetic modification is commonplace throughout the life sciences sector, from fundamental research to pharmaceutical testing. GM cellular and animal models are valuable tools for the study of many chronic diseases, the testing of pharmaceutical compounds and the development of new therapeutic strategies. Genetic modification also offers great benefits in vaccine and biopharmaceutical manufacturing, which rely heavily on the use of GM organisms for biomolecule design and production. Modifying the genome of an organism or cell line allows the incorporation of target biomolecules in specific biological contexts, as well as the transfer of a gene product from a low-producing organism to one that can produce on a commercial scale. These applications have been widely accepted for many years, with countless GM organisms approved for medical manufacturing applications by drug regulators in all major countries. Despite this widespread success within the research and pharmaceutical sectors, the use of GM organisms outside of these markets has been limited.
Despite the lack of broad acceptance for most commercial applications of GM animal products, this technology has been able to gain traction in a few market sectors. The most obvious application has been the commercialisation of transgenic animals for the production of biomolecules for therapeutic use. Cattle, sheep and goats have been used for large-scale production of antibodies, steroids and hormones - most notably insulin - for many years. In 2009, GTC Biotherapeutics received US FDA approval for bioproduction of a recombinant human antithrombin. This product - ATryn - is extracted from the milk of transgenic goats, and is the first approved biopharmaceutical to be produced using genetically engineered animals. Although this is a significant breakthrough for the commercialisation of GM animals, it is still within the pharmaceutical industry, and is a natural progression of existing cell-based technologies. Of potentially greater commercial interest is the extension of genetic engineering outside of this sector, into areas such as food production, textiles and even companion animals.
GM crops have been available in many countries since the early 1990s, and numerous cash crops - including sugar beet, soybean, corn and tomatoes - have been modified to improve resistance to disease, increase the rate of growth or enhance nutritional value. However, cultivation of these transgenic crops is generally tightly regulated, particularly within the European Union, and this, together with negative public opinion, has limited the more widespread development of GM technologies.
Similar to GM crops, many of the animals currently under development are intended to confer disease resistance, an application particularly suited to the use of zinc finger nuclease (ZFN) technology. Many diseases can be treated by the targeted deletion or modification of a host gene. With ZFNs, these targets can be modified with no footprint of genetic engineering. Due to the high costs of raising livestock, another area of focus in developing commercial GM animals has been increasing the rate of growth or size of animals. Among the first GM animals likely to be launched is a fast growing salmon from AquaBounty. The AquAdvantage Salmon is designed to reach market size in half the time of a wild type salmon, reducing costs for fish farmers and limiting the environmental impact of salmon farming by avoiding the need for ocean pens.
Although genetic engineering of animals for food is primarily driven by economic pressures, GM technologies have also been used in the companion animals market. In this sector, genetic modification can be used for practical purposes - such as the creation of hypoallergenic animals or the correction of heritable congenital defects which have arisen though inbreeding - or for purely cosmetic purposes, such as GloFish. The first example of a GM pet, GloFish are fluorescent zebrafish (Danio rerio) that have had genes encoding naturally fluorescent proteins (GFP, YFP, RFP) inserted into their genome. Developed by a group at the National University of Singapore, GloFish were originally created to develop live detection systems for water pollution. They were introduced as pets in the United States in 2003 following over two years of extensive environmental research and consultation. In Europe however, the sale and possession of GloFish is prohibited by rigorous legislation concerning the use of GM technologies.
By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels
Perhaps even more interesting from a commercial perspective is the use of GM animals in the manufacture of textiles. Silkworms - actually the larval form of the silkmoth Bombyx mori - have been used for the production of silk for thousands of years, with natural silk still produced by the cultivation of silkworms today. Silkworm cocoons are unwound to create linear silk threads, then re-spun into textiles in much the same way as cotton. Although the applications of silkworm silk are numerous, due to their unique physical and chemical properties, there is also widespread interest in the silks of several other insects.
Spider silk, in particular, offers numerous possibilities within the technical textiles industry, due to its incredible tensile strength and elasticity; characteristics which have not yet been replicated in synthetic materials. Like all insect silks, spider silk fibres consist of repetitive units of protein crystals separated by less structured protein chains. The exact properties and composition of each spider silk vary with its intended function. Major Ampullate or dragline silk, for example, is relatively hydrophobic with very high tensile strength and toughness, as it is used to form the outer rim and spokes of a web. In contrast, hydrophilic capture spiral silks, which form the inner structures of the web, are sticky and highly elastic to effectively entrap prey. This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics, for applications such as bulletproof vests, parachute canopies and automobile airbags; biomedical applications, including sutures and tendon and ligament repair; new fabrics, for sportswear and clothing; and even microelectronics.
Although the use of spider silks for microsutures has recently been reported, more widespread application of spider silk technologies is currently limited by the difficulty in producing silks on a commercially viable scale. This is due to the difficulties of rearing spiders in large numbers, due to their highly territorial and cannibalistic nature. As a result, the harvesting of spider silk fibres is extremely time consuming and labour intensive, with production of the only known spider silk garment - an 11 foot by 4 foot shawl made from golden orb spider silk - taking 150 people over five years to produce and costing in excess of £300,000!
.
To overcome these limitations, and allow future development of spider silk technologies, an alternative strategy for spider silk production is required. This makes spider silk production an obvious candidate for genetic modification, inserting spider silk genes into the genome
of other silk-making insects for bioproduction. For example, random insertion of orb spider silk genes into silkworms has allowed production of hybrid spider/silkworm silk using traditional silkworm farming strategies. The resulting hybrid silk contains approximately 10% spider silk
and has greater strength and durability than native silkworm silk, raising the possibility of using transgenic silkworms to produce pure spider silks.
Though straightforward in principle, the exchange of native silkworm genes for spider silk genes, alongside more widespread exploitation of genetic engineering, has been limited by the inherent restrictions of conventional GM technologies.
The generalised process of modifying an organism requires several capabilities, including:
- an ability to synthesise or clone the sequence of interest (if transferring genetic information);
- the capacity to grow and maintain a population of the organism of interest;
- access to the genome of the organism of interest;
- a mechanism to select animals that have received the modification of interest.
While many different techniques exist for accomplishing each of these steps, most GM technologies offer a compromise between the efficiency of the technique and the ability to accurately and precisely target the locus of interest. Viral genomic delivery technologies effectively deliver nucleic acids to cells and organisms, but fall short on ability to target specific regions of the genome, generally only allowing random insertion of genetic material. In comparison, transposase technologies allow a greater degree of targeting, but leave unwanted traces of exogenous DNA in their wake. Other methods involve the introduction of naked DNA into the cell, which results in insertion into the genome at very low frequencies, usually at random, limiting this approach to organisms that can be economically cultivated at high densities and screened in large numbers. Simply put, most techniques for genetic manipulation are random, inefficient and leave a 'footprint' of foreign DNA. While this is usually tolerated in basic research, it is not acceptable for most commercial applications, and has been a major hurdle for GM animal technologies to date.
The advent of zinc finger nuclease (ZFN) technology represents a significant breakthrough for commercialisation of GM animal products, offering precisely targeted, efficient genome editing for the first time. Commercially available through Sigma Life Science under the CompoZr brand, this technique can be used to create permanent and heritable changes to an organism of interest.
This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics
Credit Nir Nussbaum
ZFNs are a class of engineered DNA binding proteins that facilitate targeted editing of the genome by creating double-strand breaks at user-specified locations. These breaks stimulate the cell's natural DNA repair mechanisms - homologous recombination (HR) and non-homologous end joining (NHEJ) - which can be exploited to achieve rapid and permanent site-specific modification of the desired genes. While HR can be used to insert foreign DNA sequences, NHEJ allows the cell's natural processes to create precisely targeted mimics of natural mutations which leave no traces of foreign DNA. Unlike previous techniques, ZFNs offer excellent sequence specificity, binding 24 to 36 base pair target sequences to virtually eliminate off target effects, and are able to achieve modification rates exceeding 20 %, well above rates for most other technologies.
The technique is already being used to create transgenic silkworms for spider silk production. By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels.
GM technologies have revolutionised the research world and have great potential in a variety of commercial applications, but have been limited by the inherent restrictions associated with historical GM technologies. The main drawback of these technologies is their inability to accurately and efficiently target genes of interest, instead relying on random insertion of genetic material into host genomes. These limitations result in the need for extensive and costly screening to identify animals with correct transgene expression (without compromising the viability of the animal), and also result in the co-expression of both the transgene and native homologues already present.
The advent of ZFN technology signifies the beginning of an exciting new chapter in the world of genetic modification, allowing precise, targeted and efficient genome editing for the first time. Production of native spider silk using transgenic silkworms is just one example of the potential commercial applications of this innovative technology, taking us one step closer to the reality of industrial scale biomanufacturing and paving the way for an entirely new spectrum of environmentally friendly materials.
Authors:
Joseph Bedell and Brian Buntaine
Commercial Animal Technologies Group, Sigma Advanced Genetic Engineering (SAGE) Labs, Sigma Life Science
HEADLINES FOR KRAIG BIOCRAFT LABORATORIES / (KBLB):
University of Notre Dame and Kraig Biocraft Laboratories Create Artificial Spider Silk Breakthrough
September 07, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-inc-announces-that-it-has-successfully-created-transgenic-1314311.htm
Kraig Biocraft Laboratories Announces Results at Join Press Conference at the University of Notre Dame
SepraigkJKjfdSeptember 29, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-results-at-joint-press-conference-1327097.htm
Kraig Biocraft Laboratories Announces Patent Filing on Artificial Spider Silk Breakthrough
September 30, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-patent-filing-on-artificial-spider-silk-breakthrough-1327601.htm
Kraig Biocraft Laboratories Announces Application for Trademark of Spider Silk Brands
October 5, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-application-trademark-spider-silk-brands-1329547.htm
Kraig Biocraft Laboratories Changes Ticker To KBLB.PK
October 7, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-changes-ticker-to-kblbpk-1331748.htm
Kraig Biocraft Laboratories Shareholder Conference Call Today, Friday, October 8, 2010
October 8, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-shareholder-conference-call-today-friday-october-8-2010-1332000.htm
KBLB (Kraig Biocraft Laboratories) Data Feed Was Temporarily Disrupted Last Thursday, October 7, 2010
October 10, 2010
Source: http://www.marketwire.com/press-release/kblb-kraig-biocraft-laboratories-data-feed-was-temporarily-disrupted-last-thursday-october-1332536.htm
Kraig Biocraft Laboratories Posts Recording of CEO's Shareholder Conference Call Regarding Spider Silk Technology Breakthrough
October 12, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-posts-recording-ceos-shareholder-conference-call-regarding-1332988.htm
Kraig Biocraft Laboratories to Employ Artificial DNA for the Development of Its Next Generation of New Materials for the Technical Textile Market
October 19, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-employ-artificial-dna-development-its-next-generation-new-1337116.htm
Kraig Biocraft Laboratories Announces That Henry Wendt Has Joined Its Business Advisory Board
November 9, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-that-henry-wendt-has-joined-its-business-advisory-1349449.htm
Kraig Biocraft Laboratories Files 3rd Quarter Financial Statement Reflecting a Fifty Percent Reduction in Total Corporate Liabilities
November 18, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-files-3rd-quarter-financial-statement-reflecting-fifty-percent-1355837.htm
Kraig Biocraft Laboratories Announces That Raymond Kutsunai Joined Its Business Advisory Board
November 22, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-that-raymond-kutsunai-has-joined-its-business-1357617.htm
Kraig Biocraft Laboratories Releases Video of the Company's Technology Breakthrough
November 30, 2012
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-releases-video-of-the-companys-technology-breakthrough-1361164.htm
Kraig Biocraft Laboratories' CEO Issues Corporate State of Affairs Letter
December 07, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-ceo-issues-corporate-state-of-affairs-letter-1364821.htm
Kraig Biocraft Laboratories Post New Video on the Company Website
December 31, 2010
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-ceo-issues-corporate-state-of-affairs-letter-1364821.htm
Joe Cunnings Joins Kraig Biocraft Laboratories Business Advisory Board
January 24, 2011
Source: http://www.marketwire.com/press-release/joe-cunning-joins-kraig-biocraft-laboratories-business-advisory-board-1384153.htm
| | Sigma-Aldrich and Kraig Biocraft Laboratories Successfully Negotiate
License Agreement | |
Tuesday, April 12th, 2011
Source: http://www.marketwire.com/press-release/sigma-aldrich-kraig-biocraft-laboratories-successfully-negotiate-license-
agreement-pinksheets-kblb-1501105.htm
Kraig Biocraft Laboratories, Inc. (PINKSHEETS: KBLB) announced today that the Company has entered into a licensing
agreement with biotechnology giant Sigma-Aldrich (NASDAQ: SIAL), Inc.
Kraig has successfully negotiated a license to use Sigma-Aldrich's powerful zinc finger technology to accelerate its scientific
research and product development, along with an option to commercialize the resulting biomaterials in the textile and biomedical
fields.
Under the terms of the agreement announced today, Sigma will provide Kraig with its proprietary genetic engineering tools and
expertise in zinc finger nuclease to enable Kraig to significantly accelerate its product development. In addition to providing the
customized tools and technological know-how, Sigma has granted Kraig an option for a commercial license to use the technology
in the textile and biomedical markets. Sigma has agreed that upon exercise of the option Kraig will have exclusive commercial rights
to use Sigma ZFNs in conjunction with the insertion of more than two hundred proprietary spider silk sequences previously licensed
by Kraig from a third party into the silkworm genome. Sigma-Aldrich will be creating customized zinc fingers for Kraig's use in its
development of spider silk polymers and technical textiles. "Sigma-Aldrich's proprietary zinc finger technologies are extremely powerful tools which enable very precise genetic targeting," said
Kraig's CEO Kim Thompson.
"We are convinced that this technology is the key to creating advanced new products and materials. We believe that when these
customized tools are delivered by Sigma in the coming weeks, the technology will enable us to rapidly and precisely target specific
gene sequences for the creation of stronger fibers, advanced textiles and new bio-materials."
"ZFN technology has been revolutionary in genome engineering for various applications, including animal models of disease,
engineering of biopharmaceutical production systems, academic research and therapeutics," said Dr. Joseph Bedell, Director
of Sigma's Commercial AnimalTechnologyGroup. "Spider silk production is just the first example of a commercial animal
application for this exciting technology."
"Kraig has the utmost confidence in the power of Sigma's zinc finger technology," said Mr. Thompson. "Sigma's agreeing to provide
this technology by virtue of the licensing agreement to Kraig, is a real boost for us, and for the future of bio-materials and spider silk
technology. We negotiated this agreement not only to accelerate our development of advanced materials, but also because I believe
that Sigma's zinc finger technology will reinforce Kraig's competitive advantage in the field of bio-materials and advanced silk polymers.
Kraig Biocraft Laboratories expectation is that the combination of Sigma-Aldrich's revolutionary technology
and know-how, coupled with Kraig's proprietary bio-materials technology and know-how, will create synergies that will benefit both
companies.
Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are
used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key
components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science
companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its
products. Sigma-Aldrich operates in 38 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is
committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For
more information about Sigma-Aldrich, please visit its award-winning Web site athttp://www.sigma-aldrich.com. About Kraig Biocraft Laboratories Kraig Biocraft Laboratories is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with
implications for the global textile industry. For further information please visitwww.KraigLabs.com. Statements in this press release about the company's future and expectations other than historical facts are "forward-looking
statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be
no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be
identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research,"
"potential," "implications," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the
Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements.
All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially
from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable
products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to
meet the financial obligations of its business plan and to fund its continuing operations. Contact:
Ben Hansel
(720) 288-8495
Email Contact
benhansel@yahoo.com
Kraig Biocraft Laboratories Announces Shareholder Conference Call
Advisory
April 20, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-shareholder-conference-call-advisory-
pinksheets-kblb-1504541.htm
Kraig Biocraft Labs. to Hold Shareholder Conference Call to Discuss
Laboratory, Technical and Commercialization Updates
May 25, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-hold-shareholder-conference-call-discuss-laboratory
-technical-pinksheets-kblb-1518617.htm
| | | |
| |
Kraig Biocraft Laboratories Announces the Successful Creation of New Commercial
Hybrid Transgenic Silkworms
Independent Testing Confirms That the New Hybrids Are Producing Recombinant Silk Which
Significantly Exceeds Traditional Silk in Both Elasticity and Tensile Strength.
May 31, 2011 Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-successful-creation-new-commercial-hybrid-transgenic-pinksheets-kblb-1520365.htm Dr. David Kaplan Joins Kraig Biocraft Laboratories Scientific Advisory Board * (*Dr. David Kaplan subsequently withdrew from Kraig Biocraft Laboratories' Scientific Advisory Board)
June 6, 2011 Source: http://www.marketwire.com/press-release/dr-david-kaplan-joins-kraig-biocraft-laboratories-scientific-advisory-board-pinksheets-kblb-1522809.htm Kraig Biocraft Laboratories to Host a Shareholder Conference Call Later Today
Company Founder and CEO, Kim Thompson, to Host Conference Call for Shareholders and All Interested Parties June 10, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-to-host-a-shareholder-conference-call-later-today-pinksheets-kblb-1525259.htm
Kraig Biocraft Announces Interview With CEO on Chartpoppers
June 8, 2011 Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-interview-with-ceo-on-chartpoppers-pinksheets-kblb-1524084.htm Kraig Biocraft Laboratories Posts Copy of Shareholder Conference Call on Company Website
Kraig Receives First Shipment of Zinc Fingers From Sigma-Aldrich
June 14, 2011 Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-posts-copy-shareholder-conference-call-on-company-website-pinksheets-kblb-1526210.htm Kraig Biocraft Laboratories Announces $1.5 Million Agreement With Calm Seas Capital
June 30, 2011 Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-15-million-agreement-with-calm-seas-capital-pinksheets-kblb-1533602.htm Kraig Biocraft Laboratories Announces the Completion of Its First Zinc Finger Micro-Insertions
The Company's First Zinc Finger Technology Silkworms Achieve High Hatch Rate July 5, 2011 Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-completion-its-first-zinc-finger-micro-insertions-pinksheets-kblb-1534346.htm Kraig Biocraft Laboratories Completes Scheduled Second Round of Micro-Insertions Using Zinc Finger Technology
Kraig Advances Zinc Finger Technology to Modify Previously Disclosed Monster Silk
August 8, 2011 Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-completes-scheduled-second-round-micro-insertions-using-pinksheets-kblb-1546801.htm Kraig Biocraft Laboratories, Inc. Signs Spider Silk Commercial License Agreement With the University of Notre Dame
New agreement makes notre dame a kraig shareholder November 3, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-inc-signs-spider-silk-commercial-license-agreement-with-otcqb-kblb-1581536.htm Kraig Biocraft Laboratories Announces Creation of Seven New Strains of Transgenic Silkworms Using Zinc Finger Nuclease Technology
New Development Seen as a Major Leap in the Creation of Next Generation Spider Sik Technology November 14, 2011 Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-creation-seven-new-strains-transgenic-silkworms-otcqb-kblb-1586643.htm Kraig Biocraft Laboratories to Host Shareholder Conference Call Regarding Product, Scientific and Commercialization Developments
December 2, 2011 Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-host-shareholder-conference-call-regarding-product-scientific-otcqb-kblb-1593953.htm Kraig Biocraft Laboratories Announces Filing of International Patent Application for Spider-Silk and Transgenic Silkworm Technologies.
December 8, 2011 Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-filing-international-patent-application-spider-pinksheets-kblb-1596145.htm Kraig Biocraft Laboratories Recieves New Custom Zinc Finger Configurations for Advanced Fibers Development
December 12, 2011
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-receives-new-custom-zinc-finger-configurations-advanced-otcqb-kblb-1597122.htm Kraig Biocraft Laboratories Announces Peer Reviewed Publication of Spider Silk and Transgenic Silkworm Breakthroughs
Scientific Study of the Creation of Fusion Fibers and Transgenic Silkworm Is Published in the Journal Proceedings of the National Academy of Sciences SOUTH BEND, IN -- (Marketwire - Jan 5, 2012) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (PINKSHEETS: KBLB) is very happy to start the New Year by announcing that the Journal Proceedings of the National Academy of Sciences published a peer- reviewed scientific article describing the breakthrough creation of a spider silk fusion fiber, which was achieved by university scientists within the University of Wyoming and the University of Notre Dame, who are working cooperatively with Kraig Biocraft Laboratories.
The article is the first peer-reviewed scientific publication describing the creation of transgenic silkworms, which have been specifically designed to spin a spider/silkworm silk fusion fiber. The article's abstract states, "these composite fibers were, on average, tougher than the parental silkworm silk fibers and as tough as native dragline spider silk fibers. These results demonstrate that silkworms can be engineered to manufacture composite silk fibers containing stably integrated spider silk protein sequences, which significantly improve the overall mechanical properties of the parental silkworm fibers."
"The fact that a publication as prestigious as Proceedings of the National Academy of Sciences has chosen to publish these results speaks for itself as to the significance to the scientific breakthrough, "said Company founder and CEO, Kim K. Thompson. "When I founded Kraig many people in both business and scientific community said that what we were setting out to do was impossible. By maintaining a focused vision and by recruiting the very best minds in molecular biology, we have made the impossible a tangible reality."
"Congratulations to the scientific team as well as to the University of Notre Dame and the University of Wyoming. They deserve the accolades they are receiving with this publication,"continued Thompson. "Our next steps are to commercialize these developments while accelerating our development of even more advanced products. The commercial license agreement we signed in the fourth quarter of 2011 was an essential element of the former. As we move toward commercialization of these fibers, we are simultaneously moving into an advanced stage in the development of new, second generation spider silk polymers."
The scientific article described above is published, online before print January 3,2012, by the scientific journal Proceedings of the National Academy of Sciences, titled, "Silkworms Transformed with Chimeric Silkworm/Spider Silk Genes Spin Composite Silk Fibers with Improved Mechanical Properties."
"The recent publication of the analysis of genetically engineered silkworms to produce chimeric spider silks with properties of increased strength and flexibility in the prestigious journal Proceedings of the National Academy of Science represents a significant vindication of our methodology for genetically engineering and producing commercial quantities of novel protiens for medical, structural, and textile fabrics, "said Dr. Malcom Fraser. "If it were not for Kraig Biocraft Laboratories initiating this project and bringing the technologies together these results may never have materialized."
"The work is the culmination of a research effort begun more than 10 years ago with an internal award from the University of Notre Dame to my lab to develop silkworm transgenics capabilities, a two year NIH R21 grant awarded to Dr. Jarvis, Lewis, and myself, and several years of supplemental funding from Kraig Biocraft Laboratories,"Fraser continued. "The success of this research would have been impossible without the ability to carry out silkworm transgenics, mastered by Bong-Hee Sohn and Young-Soo Kim in the Fraser lab at the University of Notre Dame. This manuscript was published after an in depth peer review process, and was deemed by the publishers as a newsworthy article of the issue in which it appears, further indicating its relative importance to science and technology."
About Kraig Biocraft Laboratories
Kraig Biocraft Laboratories, Inc. (KBLB) (www.KraigLabs.com) is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of jurisdiction.
Contact:
Ben Hansel
Hansel Capital
(720) 288-8495 benhansel@yahoo.com Kraig Biocraft Laboratories Announces New Interview With CEO
January 19, 2012
Source: http://www.marketwire.com/press-release/kraig-biocraft-laboratories-announces-new-ceo-interview-otcqb-kblb-1608535.htm Kraig Biocraft Laboratories Featured In Current Issue Of Textile World
LANSING, MI -- (Marketwire - Feb 7, 2012) - Kraig Biocraft Laboratories, Inc.(OTCQB: KBLB) (PINKSHEETS: KBLB) announces that the Company's spider silk technologies, including Monster Silk, are featured as the "Quality Fabric of the Month" in the current issue of the leading textile industry publication Textile World.
An electronic version of the
Textile World article
Spider Silk:
Potential Unleashed is available online at the following link,
http://ctt.marketwire.com/?release=848923&id=1236700&type=1&url=http%3a%2f%2fwww.textileworld.com%2fArticles%2f2012%2fJanuary%2fJan-Feb_issue%2fDepartments%2fQFOM_Spider_Silk.html We are honored to be featured in the current issue of
Textile World as the "Quality Fabric of The Month", stated Company Founder and CEO, Kim Thompson. "This recognition of our achievements and our products by this leading industry publication just at the time when we are moving to commercialize our Monster Silk product could not have been more timely. I want to say thank you to the people at Textile World. For many executives in the textile industry this article will be their first glimpse of how our Company's scientific breakthroughs are making recombinant spider silk a viable, unique and exciting reality."
About Kraig Biocraft Laboratories
Kraig Biocraft Laboratories, Inc. (KBLB) (
www.KraigLabs.com) is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile
industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's
financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of jurisdiction.
Contact Information:
Ben Hansel
Hansel Capital
(720) 288-8495
benhansel@yahoo.com Kraig Biocraft Laboratories to Hold Conference Call to Discuss Commercialization and Laboratory Highlights
Feb 28, 2012 Source:
http://globenewswire.com/news-release/2012/02/28/469326/247456/en/Kraig-Biocraft-Laboratories-to-Host-Conference-Call-to-Discuss-Commercialization-and-Laboratory-Highlights.html Kraig Biocraft Laboratories to Host a Shareholder Conference Call Later Today
Comany Founder and CEO, Kim Thompson, to Discuss Commercialization and Laboratory Developments March 30, 2012
Source: http://globenewswire.com/news-release/2012/03/30/472061/250707/en/Kraig-Biocraft-Laboratories-to-Host-a-Shareholder-Conference-Call-Later-Today.html Kraig Biocraft Laboratories Announces New Laboratory Opening During Shareholder Conference Call
Company to move into New State of the Art Research Facility
April, 3 2012
Source:http://globenewswire.com/news-release/2012/04/03/472374/251068/en/Kraig-Biocraft-Laboratories-Announces-New-Laboratory-Opening-during-Shareholder-Conference-Call.html
Kraig Biocraft Laboratories Increases Zinc Finger Micro-Insertion Rate With Thousands of Targeted Genetic Insertions
Genetic Engineers Complete Five Separate Rounds of Zinc Finger Nuclease Assisted Genetic Insertions Over the Past Two Weeks
April 10, 2012
Source: http://globenewswire.com/news-release/2012/04/10/472794/251557/en/Kraig-Biocraft-Laboratories-Increases-Zinc-Finger-Micro-Insertion-Rate-With-Thousands-of-Targeted-Genetic-Insertions.html
Kraig Biocraft Laboratories is a 2012 Techtextil North America Exhibitor
LANSING, Mich., April 25, 2012 (GlobeNewswire via COMTEX) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB.PK) (the "Company") announces that the Company is an exhibitor at the Techtextil North America, held April 24-26, 2012 at the Georgia World Congress Center, Atlanta, Georgia.
This the 9th edition of Techtextil North America, North America's only dedicated show for technical textiles and nonwovens. The convention features an exhibit hall, with the Company in booth #1353, and it will serve as a means for the Company to promote its Monster Silk(TM) technology to governmental and corporate members of the textile industry.
"We targeted this year's Techtextil North America, months ago, as an important venue to mass market our Monster Silk technology, in person, and I look forward to highlighting the wide spectrum opportunity that this transgenic technology represents to certain convention attendees," said Company CEO, Kim Thomspon.
About Kraig Biocraft Laboratories
Kraig Biocraft Laboratories, Inc. (KBLB) (www.KraigLabs.com) is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of jurisdiction.
Contact:
Ben Hansel
Hansel Capital
(720) 288-8495
benhansel@yahoo.com
Kraig Biocraft Laboratories' Monster Silkworms Pleased the Crowds at 2012 Techtextil North America
Company's Attendance Generates Additional Spider Silk Interest at North America's Only Dedicated Show for Technical Textiles and Nonwovens
May 1, 2012
Source:http://globenewswire.com/news-release/2012/05/01/474964/254046/en/Kraig-Biocraft-Laboratories-Monster-Silkworms-Pleased-the-Crowds-at-2012-Techtextil-North-America.html
Kraig Biocraft Laboratories Increases Monster Silk(TM) Silkworm Yields at the Company's New Laboratory
Increase in Transgenic Silkworm Production Seen as Major Step Toward Commercialization of Monster Silk(TM)
LANSING, Mich., June 27, 2012 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB.PK) (the "Company" or "Kraig") announces that the Company's recently opened private laboratory has significantly increased Kraig's ability to generate its proprietary Monster Silk(tm) production platform silkworms.
The initial focus of the Company's facility is to assist in the commercialization of Kraig's product, Monster Silk(tm), by significantly ramping up production of the Company's proprietary transgenic silkworms that produce Monster Silk(tm), a new recombinant spider silk based fiber with potentially broad applications for consumers and industry in the multi-billion dollar marketplace for textiles and performance polymers.
"Our main goal, for the Company's recently opened laboratory, was to rapidly increase our ability to raise our Monster Silk(tm) silkworms. In the short time it's been operational, we have effectively quadrupled our ability to produce transgenic silworms, which produce Monster Silk(tm),"said Company founder and CEO, Kim Thompson.
"We knew that the increase in our laboratory production would be fundamental to the commercialization of Monster SIlk(tm)," continued Thompson. "Now that the new laboratory is working as planned, we are looking to exponentially expand our production of Monster Silk(tm)."
About Kraig Biocraft Laboratories
Kraig Biocraft Laboratories, Inc. (KBLB) (www.KraigLabs.com) is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of jurisdiction.
Contact:
Ben Hansel
Hansel Capital
(720) 288-8495 benhansel@yahoo.com Kim Thompson Posts Letter to the Shareholders on the Kraig Biocraft Laboratories Website
Aug. 6, 2012
Source: http://www.kraiglabs.com/shareholder-letter-080512.htm
Kim Thompsons' Letter to Shareholders:
August 5, 2012
Dear fellow Kraig Biocraft Laboratories shareholders,
I am writing to update you on the significant progress the Company has made in executing its business plan in 2012, and to share with you our vision of the road ahead. The Company has achieved a number of milestones in late 2011 and during the first two quarters of 2012, starting with the publication of our work on the creation of spider silk based polymers by the Proceedings of the National Academy of Sciences. That was closely followed-up by Textile World, the prestigious industry publication, featuring our spider silk based polymer, Monster Silk™, as its "technical textile of the month".
The aforementioned publications, as well as many other articles, were important catalysts that focused the spotlight on our work. Following which a number of companies approached us wanting to know if our spider silk based fibers would work in their existing product lines, or to explore the possibility of using our Monster Silk™ to enter into new markets. As discussions with these companies about the potential opportunities progressed, we decided that the best approach to commercializing our Monster Silk™ would be to work cooperatively and collaboratively, possibly on an exclusive basis, with one or two companies with existing market share in our target markets. We currently define those target markets as: military, police and DHS related applications; sportswear; other industrial and consumer applications, clothing and fashion wear; and finally, existing silk product markets.
Initially, our strategy was geared toward identifying potential Monster Silk™ commercialization partners and we've been in discussions with a number of interested companies about incorporating Monster Silk™ into their products. We then exhibited to the technical textile industry at the TechTextil trade show in late April, where Monster Silk™ sparked tremendous interest at the show.
Even though the exhibition exceeded our expectations in terms of the generation of interest and numerous contacts with new potential commercialization partners, which resulted in ongoing negotiations, some may have interpreted the lack of public comment by the Company as an indication that we stopped moving our business plan forward. Nothing could be further from the truth, as we are actually accelerating on all fronts.
The nature of the negotiations we've entered into require extreme discretion due to non-disclosure and confidentiality agreements. While we cannot comment about specific discussions, I can state my personal belief, which is that the first commercial Monster Silk™ agreements will be with military and sportswear producers.
I believe that we are currently on track to enter into memorandums of understanding and letters of intent in the near term, although we continue to receive additional inquiries and we're even in the midst of the negotiating another non-disclosure agreement as I write this letter. We are likely to select one or two defense contractors (or companies that supply defense contractors) and one or two sportswear companies, to receive some degree of partial exclusivity for the commercial development of Monster Silk™ in their respective markets.
We have a once-in-a-lifetime technology. We have taken the first two quarters of 2012 to lay the foundation of our commercialization strategy to ensure that the commercialization agreements we enter into maximize long-term shareholder value. Some of the companies that we've been talking with include household names and well-known brands.
The current negotiations approach is not unlike our bold move to secure the use of zinc finger nuclease (ZFN) technology. Although the ZFN technology negotiations with Sigma-Aldrich took time, they yielded impressive results. Because of these actions and others like it, Kraig Biocraft Laboratories was able to accelerate research and development and is now positioned for greater success.
As those of you who closely follow the Company know, we have been working with Sigma -Aldrich's ZFN technology to increase the power of our own technology. In the first half of this year we experimented with the combination of our technology with ZFN. The ZFN has proven to be so powerful that it requires an adjustment in our genetic packets. Our analysis of the data has given us increased confidence that we are on the right track for the development of fibers that are even more advanced than Monster Silk™. While that work is continuing we are also in the later stages of producing more exciting new genetic configurations for use in combination with ZFN.
Until recently all of the Company's laboratory work took place entirely within university laboratories, pursuant to collaborative research agreements, which we renewed with the University of Notre Dame. Even though we increased our financing of the collaborative research project and we are now accelerating our research at Notre Dame, in the second quarter we signed a lease for a laboratory near the university. That was a big step forward in our growth and indicates our commitment to accelerate the development of new spider silk based fibers; because we believe that we are closer to the development of our pure spider silk platform. Our new private laboratory at Innovation Park, a state of the art facility near Notre Dame, is equipped with top of the line security, including bio-sensors, which we feel is more appropriate for our technology at its current state of development.
Kraig Biocraft Laboratories has made great strides and achieved several milestones in the first two and a half quarters of 2012, plus we laid down a very solid foundation for both our commercialization program and for advanced R&D. Laying down that foundation has been grueling work, but, now that the foundation is in place, the next stages of development should be more exciting and tangible.
Our plan is to continue to build on our research knowledge to develop more advanced polymers in the near term. On the Monster Silk™ commercialization front, we are currently in privileged discussions with potential commercialization partners including some medium sized and larger companies. We anticipate that those discussions will bear fruit in the near term.
In short, I am determined to unlock the maximum value for our shareholders. We are delighted with the current positioning of our commercialization opportunities, which we're building on the foundation we laid out in the first half of the year in order to seize those opportunities. I know that this comprehensive approach takes more time, but I'm convinced that we control our own destiny and this will enable us to create far more long-term shareholder value.
Thank you for supporting the Company and taking the time to read this letter. I am very proud of our innovative Company and the ingenious technology we've developed, but I am more confident than ever that Kraig is favorably positioned to become a leading technical materials firm and I am even more intensely excited about the big future that lies ahead for Kraig Biocraft Laboratories.
Sincerely,
Kim Thompson, CEO Forward-looking statements: This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included in this press release, other than statements of historical facts, address matters that the company reasonably expects, believes or anticipates will or may occur in the future. These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. Such statements are subject to various assumptions, risks and uncertainties. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those described in the forward-looking statements.
Kraig Biocraft Laboratories Announces the Creation of New Recombinant Spider Silks
The New Spider Silks, Which Have an Unusual Red Cast and Were Designed for Superior Strength Are Collectively Designated by the Company as "Big Red" LANSING, Mich., Jan. 14, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig") announced that researchers, working pursuant to Kraig's collaborative research program, utilizing customized spider silk genetic engineering sequences, succeeded in creating a new type of recombinant spider silk, which the Company is designating as "Big Red."
The "Big Red" silk is currently being spun within the laboratory by transgenicly modified silkworms.
"'Big Red' is a composite fiber," said Company CEO, Kim Thompson. "This new type of fiber was designed to be a combination of spider silk proteins, silkworm silk proteins and protein from an unrelated species. From a genetic perspective, what significantly differentiates this material from our Monster Silk™ is the unique spider silk genetic sequence that we used, which we designed to increase strength to weight ratios. Another important difference is the incorporation of a unique protein, which gives the new fiber its designation as 'red.'
"The design for 'Big Red' derived from what we learned about the mechanical characteristics of recombinant spider silk fibers from our work with Monster Silk™," continued Thompson. "Specifically, the new fiber was designed to place more emphasis on tensile strength and slightly less emphasis on elongation. We anticipate that 'Big Red' will be a powerful arrow in our quiver as we move to commercialize Monster Silk™ and the Company is hopeful that this new material will follow it in the commercialization pipeline. In my view, the creation of Big Red demonstrates the power of our technology to continue to develop new and exciting materials."
The "Big Red" name comes in part from the fact that the fibers have a slight red cast. Under UV light, the new fibers actually glow bright red.
Thompson further stated, "The successful creation of these new materials once again validates our scientific models. Based upon the observed levels of color expression and the nature of the spider silk genetic configurations used in its creation, the hope is that it will find its own significant niche in the technical textiles marketplace. Preparation for mechanical testing of the new fiber is currently taking place."
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
Kraig Biocraft Laboratories to Launch Monster Silk(TM) Pilot Production Program
LANSING, Mich., Jan. 22, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig") announced today that it plans on launching its pilot production program for Monster Silk™, the Company's recombinant spider silk, in the first or second quarter of 2013.
The program is designed to transition Kraig from laboratory scale production to commercial. scale production of Monster Silk™. The Company anticipates launching the pilot program within the next sixty to ninety days. The initial goals for the pilot production program are to confirm production scalability and cost structures for Monster Silk™, as well as to satisfy the demand for larger scale Monster Silk™ sample requests from textile producers and product developers.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
CONTACT:
Ben Hansel
Hansel Capital, LLC.
(720) 288-8495
benhansel@yahoo.com
Kraig Biocraft Laboratories' Recombinant Spider Silk Product Development Receives Coverage From Prestigious Textile Trade Publication WTiN
LANSING, Mich., Jan. 28, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig") announced today that World Textile Information Network ("WTiN") recently published an article, entitled "Commercializing the science of spider silk", featuring the Company and its genetically engineered spider silk technologies.
As the WTiN article states, "Kraig Biocraft Laboratories has experienced growing success developing its recombinant spider silk in the last two years." The article describes Kraig's product development and includes the first published photos of the Company's new composite spider silk fiber, "Big Red." The new genetically engineered spider silk fiber takes its name from the fact that it glows bright red under UV illumination. Additional photos of what the Company hopes to be a breakthrough material will be posted on Kraig's website.
The WTiN article is available at the following link: http://ei.wtin.com/article/fQowSDlzdX2/2013/01/24/commercialising_the_science_of_spider_silk/
World Textile Information Network, established more than 100 years ago and based in the UK, is the world's leading textile news and information provider, with unrivalled textile expertise. "WTiN Intelligence" is part of the WTiN, whose magazines include- Textile Month International, Knitting International, Future Materials, Nonwovens Report International, Digital Textile, Twist and International Dyer, as well as newspapers at many of the world's leading textile exhibitions.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495
Kraig Biocraft Laboratories' Monster Silk(TM) Pilot Production Program Enters Second Stage Ahead of Schedule
Company Accelerates Recombinant Spider Silk Pilot Production After Hitting Target Objectives
LANSING, Mich., Feb. 4, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (KBLB) (the "Company" or "Kraig") announced today that it is accelerating its pilot production program, as a result of positive initial data from the first stage of the trial. The acceleration to the second phase of the program is designed to increase production capacity of Monster Silk™, the Company's recombinant spider silk, by more than tenfold over the first stage. Kraig's strategy calls on further accelerating the production program by initiating a third stage, if the program continues to meet its targets.
The first phase of the pilot production program for Monster Silk™ is continuing, even as phase two is being launched. The purpose of the program is to verify scalability and favorable production economics of Monster Silk™, to significantly increase production, and to form the basis of large scale commercial production of the Company's recombinant spider silks.
"The initial success of the first stage has given us the confidence to accelerate the program," said Kraig founder and CEO, Kim Thompson. "We are now well ahead of the schedule that we envisioned even a few weeks ago. This is a critical step forward in the commercializing of our laboratory discoveries. The launching of stage two, which I view as the heart of the pilot production program, is the most exciting and momentous event in the Company's history, second only to our invention of Monster Silk™."
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
CONTACT: Ben Hansel, Hansel Capital, LLC.
(720) 288-8495
benhansel@yahoo.com
Kraig Biocraft Laboratories and SSM Industries Sign Memorandum of Understanding to Jointly Commercialize Recombinant Spider Silk
LANSING, MI, Feb 13, 2013 (GLOBE NEWSWIRE via COMTEX) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig") and SSM Industries, Inc. ("SSM") jointly announced today that they have signed a memorandum of understanding ("MOU") to jointly commercialize Kraig's Monster Silk(TM) recombinant spider silk.
The purpose of the MOU is to develop a framework for cooperation between SSM and Kraig regarding spider silk commercialization and marketing. The parties anticipate collaborating to develop knitted and woven textiles utilizing Monster Silk(TM) and possibly other recombinant spider silks, which have been developed by Kraig or which are in its development pipeline.
The collaborative work would extend to product applications' development and marketing. Under the MOU the two companies would jointly develop select applications, for Monster Silk(TM) and other recombinant spider silks which have been developed by Kraig. This alliance is intended to support the market development for spider silk based textiles.
"SSM Industries, Inc. is an American company with a proven track record of innovation and excellence in technical textiles and protective apparel, so we are delighted to be working with them," said Kraig CEO and founder, Kim Thompson. "Today's memorandum of understanding allows us to work toward combining the capabilities of both companies in pursuing markets for knitted and woven applications of spider silk.
"This MOU is a big step forward in moving our spider silk products from the laboratory and toward meeting the increasing demand for innovative high strength materials, technical textiles and protective composites. I believe that it greatly accelerates Kraig's access to critical protective clothing and technical markets.
"This collaboration with a technical textile innovator marks a major milestone toward bringing Kraig Biocraft Laboratories' genetically engineered spider silks to mainstream markets in commercial volume," concluded Thompson.
"We are very happy to enter into co-operation between Kraig Labs and SSM Industries for developing the markets and product applications for spider silks, especially in regard to life & limb protective gear, apparel and composites," said SSM spokesman Phil Chandler.
"Both parties acknowledge the potential of working together to develop and promote recombinant spider silk related textiles and product applications," continued Mr. Chandler. "I believe the signing of the MOU between our companies marks a starting point for the development of significant markets for spider silk technologies. We are excited to be at the ground floor as we work together with Kraig to develop and grow this market segment. This new relationship demonstrates SSM Industries commitment to unlocking markets and developing innovative solutions that benefit our world and satisfy global demand."
The parties caution that while the MOU is a major step toward a binding agreement, it should not be relied upon as a guarantee that a binding agreement will be completed.
Kraig Biocraft Laboratories is in discussions with other companies to complete a consortium to drive the penetration of its recombinant spider silks into global markets.
About Kraig Biocraft Laboratories
Kraig Biocraft Laboratories, Inc. ( www.KraigLabs.com ) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
About SSM Industries
SSM Industries Inc. ( www.Ssmind.com ), based in Spring City, TN, is a full service safety and protective fabric manufacturer that manufactures flame resistant, cut resistant, and thermal fabrics.
SSM has established itself as an innovator in technical textiles and performs in-house yarn spinning, knitting, weaving, dyeing and finishing. The company produces products that are used by the U.S. military, the auto racing industry, firefighters, first responders, and industrial applications where materials with strength and protective properties are required. Internal research and development and an in-house Military certified lab to test the finished fabrics complement SSM's vast technical textile capabilities.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495
ir@kraigabs.com
Kraig Biocraft Laboratories to Host Corporate Conference Call
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Kraig" or "The Company") announces an advance conference call advisory for all shareholders and other interested parties.
LANSING, Mich., Feb. 19, 2013 (GLOBE NEWSWIRE) --
The Company plans to host a conference call for the purpose of discussing production, commercialization and scientific milestones as well as other corporate developments, featuring the Kraig's founder and CEO, Kim Thompson and is tentatively scheduled for late-March to mid-April, pending the travel schedule of Thompson and members of the scientific team.
Kraig recently announced that it signed a memorandum of understanding with SSM Industries Inc.(http://www.Ssmind.com) to jointly commercialize Kraig's Monster Silk(TM) recombinant spider silk. Other recent announcements included that the Company launched and is accelerating its Monster Silk(TM) pilot production program, as well as that it succeeded in creating "Big Red", a new type of recombinant spider silk.
The Company plans on releasing definitive details, including call-in details, time and format, at least one week prior to conference call and shareholders are invited to submit questions to http://ir@kraiglabs.com.
About Kraig Biocraft Laboratories
Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com) is a fully reporting biotechnology company that has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
Ben Hansel, Hansel Capital, LLC. (720) 288-8495
Kraig Biocraft Laboratories Provides Update on the Monster Silk (TM) Pilot Production Program's Second Stage; Program is Accomplishing Its Targeted Milestones and Remains Well Ahead of Schedule
The Ongoing Pilot Production Program's Second Phase Results are Exceeding First Phase
LANSING, Mich., Feb 25, 2013 (GLOBE NEWSWIRE via COMTEX) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig"), the leading developer of advanced spider silk based fiber technologies, announced today that the first two stages of its Monster Silk(TM) pilot production program ("program") are running ahead of schedule and that both stages of the program are on track to meet or exceed the program's goals.
The production capacity for the first two stages exceeds the Company's prior maximum capacities by a factor of four or five.
The program is designed to be the basis of the Company's large scale commercial production of its recombinant spider silks. The program is designed to run in three stages; with each successive stage launching when the previous stage's data indicates that the program is reaching, or exceeding, its benchmarks.
The current data supports the continued fast-tracking of the program, as the second phase is developing on track, surpassing the trial's initial phase in terms of capacity and success rates. The first stage continues to run ahead of expectations and is already moving to an advanced state.
"So far the pilot production program has exceeded our expectations and is confirming that our production model is fully scalable, as Phase II surpassed the program's first phase, despite the fact that it's a much larger trial," said Kraig founder and CEO, Kim Thompson. "From the beginning, this has been an ambitious program, which now appears to be rewarding our efforts. We are continuing to rapidly advance through stage two of the production program."
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry. The Company has recently launched a pilot production program as a major step toward large scale commercial production.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
Kraig Biocraft Laboratories Enters Third Phase of Its Monster Silk(TM) Pilot Production Program Ahead of Schedule
Phase Three Launches on the Heels of the Early Successes of Stages One and Two
LANSING, Mich., Feb 28, 2013 (GLOBE NEWSWIRE via COMTEX) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig"), the leading developer of advanced spider silk based fiber technologies, announced today the launch of stage 3 of its pilot production program ("program").
The program is designed to run in three stages, each launching in turn when the data from the previous stage indicates that the program is reaching its benchmarks.
"The launch of stage three indicates stages 1 and 2 are exceeding our expectations with hatch rates exceeding 60%. At the current rates of the program's development, we should be able to announce that hatchlings from the first round have begun spinning Monster Silk(TM) within the next few days," said Company founder and CEO, Kim K. Thompson.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495
ir@KraigLabs.com
Kraig Biocraft Laboratories Announces That the First Stage of Its Pilot Production Program Has Resulted in Monster Silk ™ Cocoons
Pilot Production Program is Now Producing Monster Silk ™ Cocoons
Kraig Biocraft Laboratories Announces That the First Stage of Its Pilot Production Program Has Resulted in Monster Silk(TM) Cocoons
LANSING, Mar 04, 2013 (GLOBE NEWSWIRE via COMTEX) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig"), the leading developer of advanced spider silk based fibers, announced today that the silkworm hatchlings from the first stage of its Monster Silk ™ pilot production program ("program") have now spun cocoons. The cocoons are made of Monster Sil ™, the Company's recombinant spider silk.
The program is running in three stages, with stage 1 being the first of the production stages to produce Monster Silk ™ cocoons. Stage 2 of the program is now entering a very advanced state. All three stages are ahead of schedule and are hitting or exceeding their milestones.
"Our focus on innovation and scientific excellence is transitioning well from the laboratory to production, and this ambitious pilot production program is designed to test our systems and to become the basis for large commercial scale production," said Company founder and CEO, Kim K. Thompson.
"The pilot production program goals included confirming Monster Silk's ™ production scalability; to get these results so smoothly is a tremendous boost the Company's expansion plans."
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
Kraig Biocraft Laboratories Receives Invitation From Foreign Government
Kraig Biocraft Laboratories Accepts Invitation to Explore Production Opportunities
LANSING, Mich., March 12, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig"), the leading developer of advanced spider silk based fibers, announced today that the Company has received an invitation from the council office of a foreign country to visit that country. The purpose of the invitation is to meet with governmental officials to discuss and explore the potential to produce the Company's recombinant spider silk there.
"It is a great honor for Kraig to receive this diplomatic invitation," said Company founder and CEO, Kim Thompson. "It also represents a unique opportunity. We have accepted the invitation to visit a potential production location and to meet with officials to discuss the business opportunities presented."
The Company's CEO anticipates traveling to that country and exploring the production possibilities within the next three weeks.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495
Kraig Biocraft Laboratories' Monster Silk(TM) Cocoons Now Being Reeled
Spider Silk Pilot Production Program Moves to Advanced State
LANSING, Mich., March 19, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company" or "Kraig"), the leading developer of advanced spider silk based fibers, announced today that the cocoons from the first stage of its Monster Silk™ pilot production program ("program") have been reeled into threads of the Company's recombinant spider silk as the program moves into an advanced state.
Additionally, the silkworm hatchlings from the second stage of the program have now spun cocoons that are made of Monster Silk™.
"The pilot production program has advanced well ahead of our expectations. At this rate, we will be facing some near term decisions regarding the launching of commercial production. In my opinion, we are now reaching major milestones every two to three weeks. We are undergoing tremendous developmental changes, which we believe will lead to substantial growth of our business over the next few months," said Company founder and CEO, Kim Thompson.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495
Kraig Biocraft Laboratories CEO and Scientific Advisory Board Member Meet With Government and Industry
Malcolm Fraser Invited to Meet With Indian Scientists, Government and Industry
LANSING, Mich., March 25, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company"), the leading developer of advanced spider silk based fibers, announced today that Dr. Malcolm Fraser, PhD, an influential member of the Company's scientific advisory board, is in India meeting with scientists, government officials and industry. The Company's CEO and Founder, Kim Thompson, is also traveling and is currently in another country meeting with government officials and businessmen to discus and explore production and processing opportunities for Monster Silk™ and other recombinant spider silks.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495
Kraig Biocraft Laboratories to Hold Shareholders' Meeting on April 16, 2013
Company CEO Posts Letter to Shareholders
LANSING, Mich., April 3, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company"), the leading developer of advanced spider silk based fibers, will hold a shareholder meeting on April 16, 2013. Along with the notice of meeting, the Company's founder and CEO, Kim K Thompson has posted a letter to the shareholders on the Company's website.
"We plan to continue accelerating our commercial development through 2013 and beyond," said CEO and founder Kim K Thompson. "We will also be announcing a shareholder conference call to be held sometime after the shareholders' meeting, to discuss our progress and ambitious plans for 2013 and 2014."
To view the letter to shareholders as well as the notice of the shareholder meeting along with details regarding the meeting please go to http://www.KraigLabs.com. The letter to shareholders and the notice of the shareholder meeting are also being provided to shareholders through electronic communication, for those who have previously opted for electronic communication or through the US postal service.
Furthermore, the Company is inviting shareholders to join the Kraig e-mail alert list, which will allow the Company to communicate more effectively with its shareholder community. For periodic updates, notices and important press releases, please subscribe by sending an email containing the words "shareholder, add me to the list" to http://Shareholder@KraigLabs.com.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495
Kraig Biocraft Laboratories Announces Results of 2013 Meeting of Shareholders
Attending Shareholders Unanimously Approve All Board Proposals at Meeting
LANSING, Mich., April 17, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company"), the leading developer of advanced spider silk based fibers, announced today that all of the Board of Director's proposals were approved at its meeting of shareholders held yesterday in Lansing, Michigan.
All three amendments to Company's charter listed on the meeting agenda passed with unanimous attending shareholder approval. The amendments were designed to help management advance the business model in a more streamlined fashion.
"The overwhelming support of the attending shareholders, expressed over nearly four hours of discussions, and the unanimous vote on all of management's proposals, is a validation of our plans for production and commercialization," said CEO and founder Kim Thompson. "I am looking forward to communicating further details of our plans and progress to the shareholders in an upcoming shareholder conference call."
"I would like to thank the shareholders who were able to take time out of their busy schedules to attend the meeting," continued Thompson. "It was extremely gratifying to meet other shareholders, who share many of the same visions and goals for the Company and the technology."
A copy of the three amendments to the Company charter which were approved by the shareholders at yesterday's meeting is available on the Company's website under the notice of meeting section.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495
Kraig Biocraft Laboratories Announces Plans to Launch Initial Commercial Production of Monster Silk(TM)
The Commercial Production Program Will Build on the Successes of the Pilot Production Program, Which Was Launched Earlier This Year
LANSING, Mich., May 7, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (the "Company"), the leading developer of advanced spider silk based fibers, today announced plans to launch its initial commercial production of Monster Silk™. The announcement of the Company's decision to launch commercial production follows the early successes of its of Monster Silk™ pilot production program.
"We have received strong indications of interest from potential customers and potential commercialization partners," said, CEO and founder, Kim Thompson. "Many of these companies have been very patient with the fact that our laboratory production has been limited and can not satisfy their demand for quantities of material sufficient to run test weaves and end product testing.
"Moving from our pilot production program to commercial production is a very big jump, but it is also a natural progression," continued Thompson. "We have been laying the groundwork for this expansion over the last twelve months. We are confident in the decision and we are hopeful that we can accomplish the launch during the third and fourth quarters. Our plan is to begin commercial production to meet customer needs, secure future orders and capture market share in the technical textiles market."
Kraig's pilot production program will continue to run, in order to supply continuing data and help grow the Company's production capacity.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (http://www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495
